Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography.

ABSTRACT:

Background

Atherosclerosis is a chronic inflammatory disease driven by endothelial dysfunction, cholesterol accumulation, and immune activation leading to thrombosis and vascular stenosis. While LDL-lowering therapies are firmly established, targeting the underlying inflammation is still an emerging strategy. Cholesterol crystals (CC) contribute to inflammation by activating the NLRP3 inflammasome in monocytes and promoting disease progression. Cyclodextrin (CD), an FDA-approved drug carrier, has shown atheroprotective effects by enhancing cholesterol metabolism and reducing inflammation in preclinical models. This study investigated whether CC-uptake in human monocytes, a prerequisite for inflammasome activation, is also influenced by CD pretreatment.

Methods

Human peripher

SUBMITTER: Lubbering N 

PROVIDER: S-EPMC12747169 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature